Even, Caroline

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine

Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 5,101

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations

Ho, A. L., Brana, I., Haddad, R., Bauman, J., Bible, K., Oosting, S., Wong, D. J., Ahn, M.-J., Boni, V., Even, C., et al. (2021) · Journal of Clinical Oncology

Head and Neck Cancer StudiesLung Cancer Treatments and Mutations

Cited by 208

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Peyraud, F., Guégan, J.-P., Bodet, D., Nafia, I., Fontan, L., Auzanneau, C., Cousin, S., Roubaud, G., Cabart, M., Chomy, F., et al. (2022) · Annals of Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 79